130 related articles for article (PubMed ID: 37088613)
1. Correspondence on SARS-CoV-2 Vaccine Uptake Among Patients With Thoracic Malignancies.
Kleebayoon A; Wiwanitkit V
Clin Lung Cancer; 2023 Jul; 24(5):e161. PubMed ID: 37088613
[No Abstract] [Full Text] [Related]
2. Brief Report: Declining Rates of SARS-CoV-2 Vaccine Uptake Among Patients With Thoracic Malignancies.
Meador CB; Naranbhai V; Hambelton G; Rivera J; Nabel CS; Lewinsohn R; Sakhi M; Balazs AB; Iafrate AJ; Gainor JF
Clin Lung Cancer; 2023 Jun; 24(4):353-359. PubMed ID: 36792425
[TBL] [Abstract][Full Text] [Related]
3. Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study.
Maneikis K; Šablauskas K; Ringelevičiūtė U; Vaitekėnaitė V; Čekauskienė R; Kryžauskaitė L; Naumovas D; Banys V; Pečeliūnas V; Beinortas T; Griškevičius L
Lancet Haematol; 2021 Aug; 8(8):e583-e592. PubMed ID: 34224668
[TBL] [Abstract][Full Text] [Related]
4. Post-SARS-CoV-2-vaccine shoulder pain: Is it relevant to the vaccine injection? - Correspondence.
Deng Z; Zhang X; Liu Y; Xiao J; Zheng Y; Huang Y; Xu J
Int J Surg; 2022 Apr; 100():106603. PubMed ID: 35314355
[No Abstract] [Full Text] [Related]
5. Efficacy of Severe Acute Respiratory Syndrome Coronavirus-2 Vaccine in Patients With Thoracic Cancer: A Prospective Study Supporting a Third Dose in Patients With Minimal Serologic Response After Two Vaccine Doses.
Gounant V; Ferré VM; Soussi G; Charpentier C; Flament H; Fidouh N; Collin G; Namour C; Assoun S; Bizot A; Brouk Z; Vicaut E; Teixeira L; Descamps D; Zalcman G
J Thorac Oncol; 2022 Feb; 17(2):239-251. PubMed ID: 34798306
[TBL] [Abstract][Full Text] [Related]
6. Response to "A commentary on "post-SARS-CoV-2-vaccine shoulder pain: Is it relevant to the vaccine injection? - Correspondence" (Int J Surg 2022;100:106603)".
Xu J; Zhang X; Deng Z
Int J Surg; 2022 Sep; 105():106824. PubMed ID: 35987332
[No Abstract] [Full Text] [Related]
7. Esophagitis and SARS-CoV-2 vaccine: Correspondence.
Sriwijitalai W; Wiwanitkit V
Med Clin (Barc); 2023 Feb; 160(3):137. PubMed ID: 36244857
[No Abstract] [Full Text] [Related]
8. SARS-CoV-2 Vaccine Efficacy in Patients with Hematologic Malignancies: Practical Points for Further Research.
Guven DC; Sahin TK; Akın S; Uckun FM
Oncologist; 2022 Nov; 27(11):e917-e918. PubMed ID: 36005823
[TBL] [Abstract][Full Text] [Related]
9. Heterogeneous immunogenicity of SARS-CoV-2 vaccines in cancer patients receiving radiotherapy.
Bowes CL; Naranbhai V; St Denis KJ; Lam EC; Bertaux B; Keane FK; Khandekar MJ; Balazs AB; Iafrate JA; Gainor JF; Willers H
Radiother Oncol; 2022 Jan; 166():88-91. PubMed ID: 34838892
[TBL] [Abstract][Full Text] [Related]
10. A commentary on "post-SARS-CoV-2-vaccine shoulder pain: Is it relevant to the vaccine injection? - Correspondence" (int J surg 2022;100:106603).
Mungmunpuntipantip R; Wiwanitkit V
Int J Surg; 2022 Jul; 103():106664. PubMed ID: 35623601
[No Abstract] [Full Text] [Related]
11. Communication on COVID-19 vaccine: Correspondence.
Mungmunpuntipantip R; Wiwanitkit V
J Eval Clin Pract; 2022 Apr; 28(2):178. PubMed ID: 35048474
[No Abstract] [Full Text] [Related]
12. Cellular response to COVID-19 vaccines in hematologic malignancies patients: a new hope for non-responders?
Saad Albichr I; De Greef J; Van Den Neste E; Poiré X; Havelange V; Vekemans MC; Bailly S; Yombi JC; Mzougui S; Scohy A; Kabamba-Mukadi B
Leuk Lymphoma; 2022 Mar; 63(3):743-746. PubMed ID: 34706604
[No Abstract] [Full Text] [Related]
13. Serological findings following the second and third SARS-CoV-2 vaccines in lung transplant recipients.
Bárczi E; Varga V; Nagy A; Eszes N; Jáky-Kováts Z; Müller V; Bohács A
Immun Inflamm Dis; 2022 Aug; 10(8):e646. PubMed ID: 35894705
[TBL] [Abstract][Full Text] [Related]
14. An outbreak of severe acute respiratory coronavirus virus 2 (SARS-CoV-2) infections among hospital personnel with high mRNA vaccine uptake.
Tene Y; Levytskyi K; Adler A; Halutz O; Paran Y; Goldshmidt H; Itzhaki-Alfia A; Halperin T; Stepansky S; Ben-Ami R; Henig O
Infect Control Hosp Epidemiol; 2023 Jan; 44(1):114-117. PubMed ID: 34538284
[TBL] [Abstract][Full Text] [Related]
15. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.
Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC
Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336
[TBL] [Abstract][Full Text] [Related]
16. Serologic response to a third dose of an mRNA-based SARS-CoV-2 vaccine in lung transplant recipients.
Hoffman TW; Meek B; Rijkers GT; van Kessel DA
Transpl Immunol; 2022 Jun; 72():101599. PubMed ID: 35390480
[TBL] [Abstract][Full Text] [Related]
17. SARS-CoV-2 vaccine-induced humoral and cellular immunity in patients with hematologic malignancies.
Haggenburg S; Hofsink Q; Rutten CE; Nijhof IS; Hazenberg MD; Goorhuis A
Semin Hematol; 2022 Oct; 59(4):192-197. PubMed ID: 36805887
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of COVID-19 vaccine response in patients with cancer: An interim analysis.
Tran S; Truong TH; Narendran A
Eur J Cancer; 2021 Dec; 159():259-274. PubMed ID: 34798454
[TBL] [Abstract][Full Text] [Related]
19. Third primary SARS-CoV-2 mRNA vaccines enhance antibody responses in most patients with haematological malignancies.
Cook LB; O'Dell G; Vourvou E; Palanicawandar R; Marks S; Milojkovic D; Apperley JF; Loaiza S; Claudiani S; Bua M; Hockings C; Macdonald D; Chaidos A; Pavlu J; Cooper N; Fidler S; Randell P; Innes AJ
Nat Commun; 2022 Nov; 13(1):6922. PubMed ID: 36376307
[TBL] [Abstract][Full Text] [Related]
20. Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study.
Sauré D; O'Ryan M; Torres JP; Zuniga M; Santelices E; Basso LJ
Lancet Infect Dis; 2022 Jan; 22(1):56-63. PubMed ID: 34509185
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
